Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.505
-0.122 (-19.44%)
At close: Nov 4, 2024, 4:00 PM
0.510
+0.005 (1.01%)
After-hours: Nov 4, 2024, 7:59 PM EST
Cyclacel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.08 | 0.42 | - | - | - | - | |
| Revenue Growth (YoY) | -78.55% | - | - | - | - | - | |
| Cost of Revenue | - | - | - | - | - | 4.66 | |
| Gross Profit | 0.08 | 0.42 | - | - | - | -4.66 | |
| Selling, General & Admin | 6.71 | 6.72 | 7.38 | 7.46 | 5.88 | 5.02 | |
| Research & Development | 13.58 | 19.16 | 20.27 | 14.93 | 4.76 | - | |
| Operating Expenses | 20.28 | 25.87 | 27.66 | 22.39 | 10.64 | 5.02 | |
| Operating Income | -20.2 | -25.45 | -27.66 | -22.39 | -10.64 | -9.68 | |
| Interest & Investment Income | 0.07 | 0.27 | 0.21 | 0.02 | 0.04 | 0.22 | |
| Currency Exchange Gain (Loss) | -0.25 | -0.41 | 0.23 | 0.04 | 0.02 | 0.1 | |
| Other Non Operating Income (Expenses) | 0.04 | 0.05 | 1.3 | 0.14 | 0.89 | 0.23 | |
| EBT Excluding Unusual Items | -20.36 | -25.55 | -25.92 | -22.19 | -9.68 | -9.13 | |
| Pretax Income | -20.36 | -25.55 | -25.92 | -22.19 | -9.68 | -9.13 | |
| Income Tax Expense | -2.86 | -3 | -4.72 | -3.73 | -1.24 | -1.3 | |
| Earnings From Continuing Operations | -17.51 | -22.56 | -21.2 | -18.46 | -8.45 | -7.83 | |
| Net Income | -17.51 | -22.56 | -21.2 | -18.46 | -8.45 | -7.83 | |
| Preferred Dividends & Other Adjustments | 0.1 | 0.2 | 0.2 | 0.2 | 3.98 | 0.2 | |
| Net Income to Common | -17.61 | -22.76 | -21.4 | -18.66 | -12.42 | -8.03 | |
| Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 0 | 0 | |
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 0 | 0 | |
| Shares Change (YoY) | 116.69% | 13.38% | 26.10% | 145.67% | 345.23% | 34.95% | |
| EPS (Basic) | -9.75 | -26.75 | -28.52 | -31.35 | -51.28 | -147.62 | |
| EPS (Diluted) | -9.75 | -26.75 | -28.52 | -31.35 | -51.30 | -147.62 | |
| Free Cash Flow | -11.51 | -16.12 | -20.83 | -18.57 | -8.03 | -9.46 | |
| Free Cash Flow Per Share | -6.38 | -18.94 | -27.76 | -31.20 | -33.15 | -173.83 | |
| Gross Margin | 100.00% | 100.00% | - | - | - | - | |
| Operating Margin | -25255.00% | -6060.24% | - | - | - | - | |
| Profit Margin | -22007.50% | -5418.10% | - | - | - | - | |
| Free Cash Flow Margin | -14391.25% | -3837.62% | - | - | - | - | |
| EBITDA | -20.19 | -25.42 | -27.62 | -22.35 | -10.62 | -9.66 | |
| D&A For EBITDA | 0.02 | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 | |
| EBIT | -20.2 | -25.45 | -27.66 | -22.39 | -10.64 | -9.68 | |
| Revenue as Reported | 0.42 | 0.42 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.